Jonathan Goodman, MPhil

Of the patients who completed follow-up, 60% had a targeted therapy recommendation.

RNA sequencing confirmed the alterations most frequently described in low-grade glioma and revealed rare gene fusions.

Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.

Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.

A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.

Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.

Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.

Researchers sought to determine whether inhibiting ROCK1/2 when using interferon therapy would be effective in patients with MPNs.

Researchers sought to determine whether monitoring SAA levels would be a helpful strategy for determining therapy efficacy in infants with ALL.

Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.